Neoplasms

All Conditions

Rare Diseases

Desmoplastic Small Round Cell Tumor

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

All Drugs and Chemicals

N-(2-aminoethyl)-5-isoquinolinesulfonamide

This is a phase I study of 131I-8H9 for patients with DSRCT and other 8H9-reactive solid tumors metastatic to the peritoneum.

Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.

131 I-8H9

Shakeel Modak, MD

A phase I study of Intraperitoneal Radioimmunotherapy with 131 I-omburtamab in patients \>1 year of age with desmoplastic small round cell tumors and other solid tumors involving the peritoneum.

The purpose of this study is to test the safety of a new medicine called antibody 8H9 injected into the lining of the abdomen or peritoneum, where the tumor is. This medicine is an antibody or protein which binds to certain tumors, including DSCRT. There is a small number of DSCRT which do not bind with 8H9. If the tumor does not bind with 8H9, you might not benefit from this treatment. The investigators want to find out what effects, good and/or bad, it has.

This antibody is made in mice. Radioactive iodine can be bound to this antibody to deliver radiation to the tumor. The investigators wish to determine the safety of radiolabeled 8H9 at different dose levels. This is the first study using 131I-8H9 in the peritoneum.

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Phase I Study of Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum

Assessment of toxicity of 131I-8H9 administered intraperitoneally.

Assessment of maximal tolerated dose of 131I-8H9 administered intraperitoneally

Assessment of the pharmacokinetics for IP 131I-8H9 administered intraperitoneally

Assessment of the response of DSRCT and other solid tumors to 131 I-8H9 administered intraperitoneally

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum	NCT01099644	Peritoneal Canc...	131 I-8H9	1 Year -	Y-mAbs Therapeutics
Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum	NCT01099644	Peritoneal Canc...	131 I-8H9	1 Year -	Y-mAbs Therapeutics

Spots Global Cancer Trial Database for intraperitoneal radioimmunotherapy